Silver Lake Sues Icahn to Kill the Endeavor 'Appraisal Arbitrage' Trade — And Force Every PE Take-Private With a Public Subsidiary to Read Its Own Deal Math

Silver Lake is not asking the court to value Endeavor at any specific number — it is asking the court, before the merits stage, to declare that none of the hedge funds now seeking appraisal are even entitled to demand one. The complaint, filed in Delaware's Court of Chancery on September 21, 2026, calls the funds \"opportunistic arbitrageurs\" who \"began scooping up Endeavor stock, even chasing it above the deal price\" after Silver Lake's April 2, 2024 announcement of $27.50 per share. The thesis is procedural: under Section 262 of the Delaware General Corporation Law, the appraisal remedy exists for stockholders who actually opposed the merger. If the Court buys Silver Lake's framing, the $4.1 billion in pending appraisal petitions collapses before a single merits trial.

Endeavor's accounting niceties obscured a brutal market-arithmetic problem for Silver Lake: between announcement and closing, TKO Group Holdings's share price rose sharply, such that Endeavor's roughly 61% stake in TKO alone traded at more than $27.50 per Endeavor share. Endeavor's stockholders never got a chance to vote on that implied uplift. Where appraisal often loses is where deal-time market signals line up with the negotiated price; here, the public market wasscreaming that Silver Lake had bought Endeavor at a meaningful discount from day one.

Put differently, the publicly traded pieces of Endeavor — TKO Group, sports rights, IMG, On Location — were easier to value than usual because TKO itself is listed on the NYSE. That transparency is what makes Endeavor the canonical case for hedge funds arguing that the deal was materially underpriced. TKO Group Holdings's stock itself now trades at $192.28, giving Endeavor's ~61% stake an implied market value that exceeds the entire enterprise value Silver Lake paid in 2025.

The September 21 complaint makes four fact-specific allegations, all of which target the funds' standing under Section 262 rather than the merits of the $27.50 price. None of them accuse any defendant of leaking confidential deal information or shorting Endeavor — Silver Lake's play is procedural disqualification, not securities fraud.

Carl Icahn never filed an appraisal petition. He filed a separate fiduciary-duty class action alleging Silver Lake and Endeavor management breached their duties and \"took Endeavor's assets to benefit insiders.\" That is a different legal vehicle with different procedural rules — appraisal is a statutory dissent remedy; the fiduciary suit is common-law equitable litigation. The Chancery named the Icahn Enterprises/Handelsbanken group co-lead plaintiff in the underlying appraisal action on September 29, 2025, citing their combined 27.5 million Endeavor shares — about $757 million at the deal price.

Naming Icahn alongside the funds is what makes this suit distinctive. Silver Lake's theory is that the class-action plaintiff and the appraisal petitioners are operationally the same trade — accumulate post-announcement, then litigate simultaneously through the appraisal statute and the fiduciary class action. Even if the September 21 injunction does no more than force discovery into the funds' trading records and Icahn's communications with them, it would expose how a fiduciary-theory plaintiff and a fair-value-theory plaintiff co-ordinated the attack. That evidentiary record is what Silver Lake can deploy in every subsequent take-private's appraisal docket.

Procedurally, the Court of Chancery will likely rule on the injunction motion before any merits trial, because the standing question — were these plaintiffs ever \"dissenting stockholders\"? — is dispositive of the entire appraisal queue. A Silver Lake win guts the pending petitions and effectively pulls the rug out from under any future complaint that follows an identical playbook. A Silver Lake loss puts the case into merits discovery, where TKO Group Holdings's listed share price becomes the most powerful objective valuation evidence in the room, and where interest continues to accrue at the 9.5% statutory rate.